Very recently, a β-arrestin-biased AT1R agonist TRV027 could prevent aortic aneurysm and respective mortality via distinct mechanisms than the AT1R blocker, Olmesartan (111). This evidence concerns the gene AGTR1 and aortic aneurysm.